secwatch.observer — SEC 8-K summary
======================================

Issuer:     Theravance Biopharma, Inc. (TBPH)
CIK:        0001583107
Form:       8-K
Filed at:   2023-10-30T23:59:59+00:00
Accession:  0001104659-23-112631
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Theravance settles YUPELRI patent litigation with Teva; generic launch delayed to April 2039
--------------------------------------------------------------------------------

- Settlement with Teva resolves ANDA litigation; Teva gets license to launch generic on or after April 23, 2039.
- License is royalty-free, non-exclusive, non-sublicensable; subject to DOJ/FTC review and customary exceptions.
- Litigation against six other ANDA filers (Accord, Cipla, Eugia, Lupin, Mankind, Orbicular) remains pending.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1583107/000110465923112631/0001104659-23-112631-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1583107/000110465923112631/tm2329363d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-112631

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer